Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Gulf Pharmaceutical Industries PSC's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Gulf Pharmaceutical Industries PSC's highest Yield on Cost was 7.44. The lowest was 4.22. And the median was 5.15.
ADX:JULPHAR's 5-Year Yield-on-Cost % is not ranked *
in the Medical Distribution industry.
Industry Median: 3.12 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Gulf Pharmaceutical Industries PSC 5-Year Yield-on-Cost % Related Terms
ADX:JULPHAR vs MCK, COR, CAH: 5-Year Yield-on-Cost % Comparison
For the Medical Distribution subindustry, Gulf Pharmaceutical Industries PSC's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gulf Pharmaceutical Industries PSC 5-Year Yield-on-Cost % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Gulf Pharmaceutical Industries PSC's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Gulf Pharmaceutical Industries PSC's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) has a 5-Year Yield-on-Cost % of 0.00 as of Sep. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. Over the past decade, Gulf Pharmaceutical Industries PSC's 5-Year Yield-on-Cost % has ranged from 4.22 to 7.44. According to the industry distribution chart, Gulf Pharmaceutical Industries PSC ranks #999999 out of 70 companies in the Medical Distribution industry.
Is Gulf Pharmaceutical Industries PSC's 5-Year Yield-on-Cost % too high?
Gulf Pharmaceutical Industries PSC's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 4.22 to a high of 7.44. Based on the distribution chart, Gulf Pharmaceutical Industries PSC ranks #999999 out of 70 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Gulf Pharmaceutical Industries PSC has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gulf Pharmaceutical Industries PSC's 5-Year Yield-on-Cost % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Gulf Pharmaceutical Industries PSC ranks #999999 out of 70 companies for 5-Year Yield-on-Cost %. This places Gulf Pharmaceutical Industries PSC in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.12. Historically, Gulf Pharmaceutical Industries PSC's own 5-Year Yield-on-Cost % has ranged from 4.22 to 7.44 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Distribution company?
The median 5-Year Yield-on-Cost % among Medical Distribution companies is 3.12, based on 70 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. For the Medical Distribution industry, the median 5-Year Yield-on-Cost % is 3.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gulf Pharmaceutical Industries PSC's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gulf Pharmaceutical Industries PSC stock overvalued right now?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) is currently considered Fairly Valued. The stock's GF Value™ is د.إ1.12, compared to a current price of د.إ1.06 — trading 5.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Gulf Pharmaceutical Industries PSC's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Gulf Pharmaceutical Industries PSC (ADX:JULPHAR), the current 5-Year Yield-on-Cost % is 0.00 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC stock appears to be undervalued.
The current stock price of د.إ1.06 is trading 5.4% below its estimated GF Value™ of د.إ1.12.
GuruFocus considers Gulf Pharmaceutical Industries PSC to be Fairly Valued.
Key valuation signals for ADX:JULPHAR:
5-Year Yield-on-Cost %: 0.00
GF Value™: د.إ1.12 vs. price of د.إ1.06 (5.4% below fair value)
No single metric tells the full story. See the ADX:JULPHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Trading, Investments, and others. The majority of its revenue is generated from the Manufacturing segment. The geographical segments are UAE, Other GCC countries, and Other countries. It derives maximum revenue from UAE. Its business is centered around General Medicines in the retail pharmacy channel and hospitals as well as speciality Products. Its medicines also targets therapeutic segments such as Diabetes, Gastrointestinal Tract (GIT), Respiratory, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Erectile Dysfunction and Others.
64GF Score
Get the complete analysis for ADX:JULPHAR
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADX:JULPHAR has been successfully added to your 
